{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:13:50Z","timestamp":1790691230165,"version":"4.1.0"},"reference-count":48,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Thyroid\u00ae"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Patients with Graves' disease are commonly treated with radioiodine. There remains controversy over whether the aim of treatment should be to achieve euthyroidism or hypothyroidism, and whether treatments should be administered with standard levels of radioactivity or personalized according to the radiation absorbed doses delivered to the thyroid. The aim of this review was to investigate whether a relationship exists between radiation absorbed dose and treatment outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis of all reports published before February 13, 2020, were performed using PubMed, Web of Science, OVID MEDLINE, and Embase. Proportion of patients achieving nonhyperthyroid status was the primary outcome. Secondary outcomes were proportion of patients who were specifically euthyroid or hypothyroid. A random-effects meta-analysis of proportions was performed for primary and secondary outcomes, and the impact of the radiation absorbed dose on treatment outcome was assessed through meta-regression. The study is registered with PROSPERO (CRD42020175010).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 1122 studies were identified of which 15, comprising 2303 Graves' disease patients, were eligible for the meta-analysis. A strong association was found between radiation absorbed dose and nonhyperthyroid and hypothyroid outcomes (odds ratio [OR]\u2009=\u20091.11 [95% confidence interval {CI} 1.08\u20131.14] and OR\u2009=\u20091.09 [CI 1.06\u20131.12] per 10 Gy increase). Higher rates of euthyroid outcome were found for radiation absorbed doses within the range 120\u2013180 Gy when compared with outside this range (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20091172, OR\u2009=\u20092.50 [CI 1.17\u20135.35],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.018). A maximum euthyroid response of 38% was identified at a radiation absorbed dose of 128 Gy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The presented radiation absorbed dose\u2013response relationships can facilitate personalized treatment planning for radioiodine treatment of patients with Graves' disease. Further studies are required to determine how patient-specific covariates can inform personalized treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/thy.2021.0302","type":"journal-article","created":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T01:32:40Z","timestamp":1633138360000},"page":"1829-1838","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":27,"title":["A Systematic Review and Meta-Analysis of the Relationship Between the Radiation Absorbed Dose to the Thyroid and Response in Patients Treated with Radioiodine for Graves' Disease"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9947-2857","authenticated-orcid":false,"given":"Jan","family":"Taprogge","sequence":"first","affiliation":[{"name":"Joint Department of Physics, Royal Marsden NHSFT, Sutton, United Kingdom."},{"name":"The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9390-461X","authenticated-orcid":false,"given":"Paul M.D.","family":"Gape","sequence":"additional","affiliation":[{"name":"Joint Department of Physics, Royal Marsden NHSFT, Sutton, United Kingdom."},{"name":"The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0828-0938","authenticated-orcid":false,"given":"Lily","family":"Carnegie-Peake","sequence":"additional","affiliation":[{"name":"Joint Department of Physics, Royal Marsden NHSFT, Sutton, United Kingdom."},{"name":"The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8217-5810","authenticated-orcid":false,"given":"Iain","family":"Murray","sequence":"additional","affiliation":[{"name":"Joint Department of Physics, Royal Marsden NHSFT, Sutton, United Kingdom."},{"name":"The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4292-6149","authenticated-orcid":false,"given":"Jonathan I.","family":"Gear","sequence":"additional","affiliation":[{"name":"Joint Department of Physics, Royal Marsden NHSFT, Sutton, United Kingdom."},{"name":"The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Leek","sequence":"additional","affiliation":[{"name":"Joint Department of Physics, Royal Marsden NHSFT, Sutton, United Kingdom."},{"name":"The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve L.","family":"Hyer","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Epsom and St Helier University Hospitals NHS Trust, Carshalton, Surrey, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4743-2276","authenticated-orcid":false,"given":"Glenn D.","family":"Flux","sequence":"additional","affiliation":[{"name":"Joint Department of Physics, Royal Marsden NHSFT, Sutton, United Kingdom."},{"name":"The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,12,16]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-017-0182-7"},{"key":"e_1_3_5_3_2","unstructured":"Royal College of Physicians. 2007. Radioiodine in the Management of Benign Thyroid Disease: Clinical Guidelines. Report of a Working Party. RCP London."},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1536-8"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0229"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000490384"},{"key":"e_1_3_5_7_2","unstructured":"NICE. 2019. Thyroid disease: assessment and management\u2014NICE guideline [NG145]. Available at https:\/\/www.nice.org.uk\/guidance\/ng145 (accessed May26 2021)."},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-013-2387-x"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03291.x"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1997.7.205"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.19080\/JPCR.2018.05.555669"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14340"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_5_14_2","doi-asserted-by":"crossref","unstructured":"Moola S Munn Z Tufanaru C Aromataris EC Sears K Sfetc R Currie MJ Lisy K Qureshi R Mattis P Mu PF 2020 Chapter 7: Systematic reviews of etiology and risk. JBI Manual for Evidence Synthesis ed. E. Aromataris and Z. Munn. 2020. Available at https:\/\/synthesismanual.jbi.global (accessed May26 2021).","DOI":"10.46658\/JBIRM-17-06"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/jech-2013-203104"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.1995.tb01547.x"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/10543406.2012.756496"},{"key":"e_1_3_5_19_2","doi-asserted-by":"crossref","first-page":"e0146021","DOI":"10.1371\/journal.pone.0146021","article-title":"Dose-response analysis using R","volume":"10","author":"Ritz C","year":"2016","unstructured":"Ritz C, , Baty F, , Streibig JC, , Gerhard D. 2016. Dose-response analysis using R. PLoS One, 10:e0146021.","journal-title":"PLoS One"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmp.2016.05.059"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1999.9.865"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1996.441788000.x"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1972.00320010037002"},{"key":"e_1_3_5_24_2","first-page":"1632","article-title":"Optimized dose planning of radioiodine therapy of benign thyroidal diseases","volume":"34","author":"Bockisch A","year":"1993","unstructured":"Bockisch A, , Jamitzky T, , Derwanz R, , Biersack HJ. 1993. Optimized dose planning of radioiodine therapy of benign thyroidal diseases. J Nucl Med, 34:1632\u20131638.","journal-title":"J Nucl Med"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0300-2977(96)00037-X"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1410117"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00173041"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2005.20.218"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002590100621"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000000826"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.3413\/nukmed-0087"},{"key":"e_1_3_5_32_2","first-page":"496","article-title":"Personalization of radioiodine treatment for Graves' disease: a prospective, randomized study with a novel method for calculating the optimal 131I-iodide activity based on target reduction of thyroid mass","volume":"56","author":"Orsini F","year":"2012","unstructured":"Orsini F, , Traino AC, , Grosso M, , Guidoccio F, , Boni G, , Volterrani D, , Mariani G. 2012. Personalization of radioiodine treatment for Graves' disease: a prospective, randomized study with a novel method for calculating the optimal 131I-iodide activity based on target reduction of thyroid mass. Q J Nucl Med Mol Imaging, 56:496\u2013502.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"e_1_3_5_33_2","first-page":"56","article-title":"The influence of thiamazole, lithium carbonate, or prednisone administration on the efficacy of radioiodine treatment 131I in hyperthyroid patients","volume":"61","author":"Oszukowska L","year":"2010","unstructured":"Oszukowska L, , Knapska-Kucharska M, , Makarewicz J, , Lewi\u0144ski A. 2010. The influence of thiamazole, lithium carbonate, or prednisone administration on the efficacy of radioiodine treatment 131I in hyperthyroid patients. Endokrynol Pol, 61:56\u201361.","journal-title":"Endokrynol Pol"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-002-0877-3"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03347067"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-014-0398-4"},{"key":"e_1_3_5_37_2","first-page":"301","article-title":"Radioiodine therapy of hyperfunctioning thyroid nodules: usefulness of an implemented dose calculation algorithm allowing reduction of radioiodine amount","volume":"57","author":"Schiavo M","year":"2013","unstructured":"Schiavo M, , Bagnara MC, , Pomposelli E, , Altrinetti V, , Calamia I, , Camerieri L, , Giusti M, , Pesce G, , Reitano C, , Bagnasco M, , Caputo M. 2013. Radioiodine therapy of hyperfunctioning thyroid nodules: usefulness of an implemented dose calculation algorithm allowing reduction of radioiodine amount. Q J Nucl Med Mol Imaging, 57:301\u2013307.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00173482"},{"key":"e_1_3_5_39_2","first-page":"260","article-title":"Dosage determination with radioactive isotopes; practical considerations in therapy and protection","volume":"59","author":"Marinelli LD","year":"1948","unstructured":"Marinelli LD, , Quimby EH, , Hine GJ. 1948. Dosage determination with radioactive isotopes; practical considerations in therapy and protection. Am J Roentgenol Radium Ther, 59:260\u2013281.","journal-title":"Am J Roentgenol Radium Ther"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006231-200605000-00005"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1833"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.1.71"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3459"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30059-2"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1347"},{"key":"e_1_3_5_46_2","first-page":"1539","article-title":"Transient hypothyroidism after iodine-131 therapy for Grave's disease","volume":"36","author":"G\u00f3mez N","year":"1995","unstructured":"G\u00f3mez N, , G\u00f3mez JM, , Orti A, , Gavald\u00e0 L, , Villabona C, , Leyes P, , Soler J. 1995. Transient hypothyroidism after iodine-131 therapy for Grave's disease. J Nucl Med, 36:1539\u20131542.","journal-title":"J Nucl Med"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39114.670150.BE"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0000000000000288"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-020-00332-9"}],"container-title":["Thyroid\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/thy.2021.0302","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2021.0302","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2021.0302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:08:33Z","timestamp":1777586913000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/thy.2021.0302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1089\/thy.2021.0302"],"URL":"https:\/\/doi.org\/10.1089\/thy.2021.0302","relation":{},"ISSN":["1050-7256","1557-9077"],"issn-type":[{"value":"1050-7256","type":"print"},{"value":"1557-9077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]}}}